🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise around the world, with estimates suggesting in excess of 82 million infections per year. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the face of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Clearance

One new antibiotic, also known as Nuzolvence, was authorized by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to major issues, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, was also approved in concurrent days. This medication, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone represents a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Outcomes and Global Access

Based on data detailed in a prominent scientific publication, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which uses a dual-drug approach. The research involved nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians treating patients have voiced hope. Having a one-pill regimen of this kind is seen as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.